Pill burden decreases and antiretroviral regimens simplify for many of the participants who start lenacapavir.

Ang Pagyakap sa Linya” tells audiences that a big part of curbing the spread of the HIV is by embracing the realities of it, ...

In Malaysia, recent data from the Ministry of Health indicate that Human Immunodeficiency Virus (HIV) notifications remain a ...

The United States, whose deep cuts to foreign aid this year under President Trump have severely impacted Africa’s health ...

Despite the success of antiretroviral therapy (ART) in controlling HIV replication, a definitive cure remains elusive due to ...

A Taipei Metro train has been decorated to spread awareness about HIV, aiming to reduce fear, stigma and discrimination ...

A Q&A With Shauna Applin, ARNP. AJMC: Despite substantial therapeutic advances since the 1980s, the US is not on pace to achieve the goals of the Ending the HIV Epidemic (EHE) public health initiative ...

UNAIDS issues a stark warning about the potential resurgence of HIV due to significant funding cuts ahead of World AIDS Day ...

Opportunistic infections target people with weakened immune systems, including those with HIV. These conditions can lead to ...

Gilead's Phase 3 ARTISTRY-1 trial shows its single-tablet HIV regimen of bictegravir and lenacapavir matches the efficacy and safety of current therapy.

Cryo-EM revealed HIV-1 integrase’s distinct structures as it shifts between its two roles of DNA integration and RNA-binding.

Despite effective HIV medication, the immune system of people with HIV remains disrupted in the long term. Researchers at Amsterdam UMC investigated whether this dysregulation can be prevented by ...